LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: Elsevier
Languages: English
Types: Article
Subjects:

Classified by OpenAIRE into

mesheuropmc: embryonic structures
OBJECTIVE: To examine the potential effects of intravenous magnesium sulphate (MgSO4) administration on antepartum and intrapartum fetal heart rate (FHR) parameters measured by cardiotocography (CTG) or electronic fetal monitoring (EFM). METHODS: We undertook a systematic review of randomized controlled trials, observational studies, and case series. Studies were reviewed independently by two reviewers and qualitatively analyzed with regard to CTG/EFM parameters (baseline FHR, variability and acceleration-deceleration patterns), types of participants, interventions offered, and outcomes reported. RESULTS: Of 18 included studies, two were RCTs (72 women); 12 were prospective observational studies (269 women), 10 of which were of a pre- and post-intervention design; one was a prospective cohort study (36 women) and three were retrospective cohort studies (555 women). Lower baseline FHR was associated with MgSO4 exposure in seven of nine relevant studies. Decreased FHR variability was reported in nine of 12 relevant studies. Reductions in reactivity or acceleration pattern were seen in four of six relevant studies without an increase in decelerative patterns. All changes were small and not associated with adverse clinical outcomes. CONCLUSION: Maternal administration of MgSO4 for eclampsia prophylaxis/treatment, tocolysis or fetal neuroprotection appears to have a small negative effect on FHR, variability, and accelerative pattern, but is not sufficient clinically to warrant medical intervention.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 3. Cunningham FG, MacDonald PC, Gant NF, Leveno KJ, Gilstrap LC III, Hankins GDV, et al. Williams' obstetrics. 20th ed. Stamford, CT: Appleton & Lange; 1997:721-7, 818.
    • 4. Freeman, RK, Garite TJ, Nageotte MP. Fetal heart rate monitoring. 2nd ed. Baltimore: Williams & Wilkins; 1991:71.
    • 5. Garite TJ. Intrapartum fetal evaluation. In: Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: normal and problem pregnancies. 5th ed. Philadelphia, PA: Churchstone 6. Livingston Elsevier; 2007:364-95.
    • 6. Alfirevic Z, Devane D, Gyte GML. Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database Syst Rev 2013, Issue 5. Art. No.: CD006066. doi: 10.1002/14651858.CD006066.pub2.
    • 7. Magee L, Sawchuck D, Synnes A, von Dadelszen P. Magnesium sulphate for fetal neuroprotection. J Obstet Gynaecol Can 2011;33(5): 516-29.
    • 8. MAG-CP Working Group. MAG-CP FAQ. Vancouver (BC): Canadian Perinatal Network; 2014. Available at: https://www.cpn-rpc.org/MAGCP/ faq.aspx. Accessed September 10, 2013.
    • 9. Chesley LC. Parenteral magnesium sulfate and the distribution, plasma levels, and excretion of magnesium. Am J Obstet Gynecol 1979;133(1):1-7.
    • 10. Hallak M, Martinez-Poyer J, Kruger ML, Hassan S, Blackwell SC, Sorokin Y. The effect of magnesium sulfate on fetal heart rate parameters: a randomized, placebo-controlled trial. Am J Obstet Gynecol 1999;181(5 Pt 1):1122-7.
    • 11. Twickler DM, McIntire DD, Alexander JM, Leveno KJ. Effects of magnesium sulfate on preterm fetal cerebral blood flow using Doppler analysis: a randomized controlled trial. Obstet Gynecol 2010;115(1):21-5.
    • 12. Atkinson MW, Belfort MA, Saade GR, Moise KJ Jr. The relation between magnesium sulfate therapy and fetal heart rate variability. Obstet Gynecol 1994;83(6):967-70.
    • 13. Canez MS, Reed KL, Shenker L. Effect of maternal magnesium sulfate treatment on fetal heart rate variability. Am J Perinatol 1987;4(2):167-70.
    • 14. Guzman ER, Conley M, Stewart R, Ivan J, Pitter M, Kappy K. Phenytoin and magnesium sulfate effects on fetal heart rate tracings assessed by computer analysis. Obstet Gynecol 1993;82(3):375-9.
    • 15. Hiett AK, Devoe LD, Brown HL, Watson J. Effect of magnesium on fetal heart rate variability using computer analysis. Am J Perinatol 1995;12(4):259-61.
    • 16. Lin CC, Pielet BW, Poon E, Sun G. Effect of magnesium sulfate on fetal heart rate variability in preeclamptic patients during labor. Am J Perinatol 1988;5(3):208-13.
    • 17. Miller JM Jr, Keane MW, Horger EO 3rd. A comparison of magnesium sulfate and terbutaline for the arrest of premature labor. A preliminary report. J Reprod Med 1982;27(6):348-51.
    • 18. Peaceman AM, Meyer BA, Thorp JA, Parisi VM, Creasy RK. The effect of magnesium sulfate tocolysis on the fetal biophysical profile. Am J Obstet Gynecol 1989;161(3):771-4.
    • 19. Petrie RH, Yeh SY, Murata Y, Paul RH, Hon EH, Barron BA, et al. The effect of drugs on fetal heart rate variability. Am J Obstet Gynecol 1978;130(3):294-9.
    • 20. Sherer DM. Blunted fetal response to vibroacoustic stimulation associated with maternal intravenous magnesium sulfate therapy. Am J Perinatol 1994;11(6):401-3.
    • 21. Stallworth JC, Yeh SY, Petrie RH. The effect of magnesium sulfate on fetal heart rate variability and uterine activity. Am J Obstet Gynecol 1981;140(6):702-6.
    • 22. Vigil-De Gracia P, Simiti E, Lora Y. Intrapartum fetal distress and magnesium sulfate. Int J Gynaecol Obstet 2000;68(1):3-6.
    • 23. Wright JW, Ridgway LE, Wright BD, Covington DL, Bobitt JR. Effect of MgSO4 on heart rate monitoring in the preterm fetus. J Reprod Med 1996;41(8):605-8.
    • 24. Kamitomo M, Sameshima H, Ikenoue T, Nishibatake M. Fetal cardiovascular function during prolonged magnesium sulfate tocolysis. J Perinat Med 2000;28(5):377-82.
    • 25. Duffy CR, Odibo AO, Roehl KA, Macones GA, Cahill AG. Effect of magnesium sulfate on fetal heart rate patterns in the second stage of labor. Obstet Gynecol 2012;119(6):1129-36.
    • 26. Petrikovsky BM, Vintzileos AM. Magnesium sulfate and intrapartum fetal behavior. Am J Perinatol 1990;7(2):154-6.
    • 27. Stewart AM, Macones GA, Odibo AO, Colvin R, Cahill AG. Changes in fetal heart tracing characteristics after magnesium exposure. Am J Perinatol 2013; doi:10.1055/s-0033-1363499.
    • 28. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 106: Intrapartum fetal heart rate monitoring: Nomenclature, interpretation, and general management principles. Obstet Gynecol 2009;114(1):192-202. doi:10.1097/AOG.0b013e3181aef106; 10.1097/ AOG.0b013e3181aef106.
    • 29. National Institute for Health and Care Excellence. Intrapartum care: care of healthy women and their babies during childbirth. NICE guideline CG55, September 2007. Available at: http://publications.nice.org.uk/ intrapartum-care-cg55. Accessed April 21, 2014.
    • 30. Robinson B. A review of NICHD standardized nomenclature for cardiotocography: the importance of speaking a common language when describing electronic fetal monitoring. Rev Obstet Gynecol 2008;1(2):56-60.
    • 31. Dawes G, Meir YJ, Mandruzzato GP. Computerized evaluation of fetal heart-rate patterns. J Perinat Med 1994;22(6):491-9.
    • 32. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009;(1):CD004661.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article